Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:07:17.325Z.
Calculation as of: 2026-10-06T18:07:17.325Z.
Quote observation: 2026-10-06T18:05:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$3.03B
Price/FCF Ratio
77.27
TTM Avg
106.42
3Y Avg
106.42
5Y Avg
106.42
Market Cap
$3.08B
Price/FCF Ratio
N/A
TTM Avg
20.86
3Y Avg
20.86
5Y Avg
20.86
Market Cap
$3.10B
Price/FCF Ratio
N/A
TTM Avg
16.27
3Y Avg
21.05
5Y Avg
21.05
Market Cap
$2.80B
Price/FCF Ratio
35.42
TTM Avg
52.84
3Y Avg
87.29
5Y Avg
87.29
Market Cap
$3.19B
Price/FCF Ratio
51.87
TTM Avg
53.17
3Y Avg
53.17
5Y Avg
80.88
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $2.99B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.03B | 77.27 | 106.42 | 106.42 | 106.42 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.08B | N/A | 20.86 | 20.86 | 20.86 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.10B | N/A | 16.27 | 21.05 | 21.05 |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.84B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.80B | 35.42 | 52.84 | 87.29 | 87.29 |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 54.41 | 72.35 | 93.08 | 93.08 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 51.87 | 53.17 | 53.17 | 80.88 |
| Precigen, Inc. (PGEN)vs › | $2.71B | N/A | 399.46 | 399.46 | 399.46 |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.67B | N/A | 146.96 | 80.20 | 82.43 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
